Genius Sports Sees Analyst Ratings Shift Amid Revenue Growth

Analysts show mixed sentiments on Genius Sports stock, with a notable revenue growth of 18.16%. The average price target rose to $11.25, indicating cautious optimism.

Date: 06-01-2025

AI Rating: 7

Analyst Ratings Overview: Genius Sports (NYSE: GENI) is experiencing varied analyst ratings with a majority being bullish overall. In the last three months, a total of 10 analysts expressed their views, with 7 delivering a bullish rating. However, this sentiment appears to have slightly shifted in the last 30 days, indicating some indecision in the market.

Revenue Growth: A significant aspect of Genius Sports's financial performance is its reported revenue growth rate of 18.16% as of September 30, 2024. This performance surpasses industry averages within the Consumer Discretionary sector, showcasing the company's ability to expand its top-line earnings, which positively impacts stock valuations.

Net Margin: Genius Sports demonstrates financial health with a net margin of 10.4%, significantly outpacing industry benchmarks. This indicates effective cost management and could lead to favorable market perception, reflecting positively on its stock price.

Return on Equity (ROE): Furthermore, Genius Sports holds an exceptional ROE of 2.26%, which surpasses industry averages. This figure underscores the company's efficient use of equity capital and strong financial condition, potentially boosting investor confidence and stock performance.

Price Targets: Analysts have adjusted their price targets positively, with the current average target climbing to $11.25 from $9.75, marking a significant 15.38% increase. This upward momentum in price targets can stimulate buying interest among investors, positively influencing the share price.

Debt Management: The company's below-average debt-to-equity ratio of 0.01 highlights a prudent financial strategy. This low leverage indicates a risk-averse approach, a quality that investors often favor, as it mitigates financial distress risks.

Stocks: GENI